Kölsch H, Lütjohann D, Jessen F, Urbach H, von Bergmann K, Maier W, Heun R
Department of Psychiatry, University of Bonn, Bonn, Germany.
J Neural Transm (Vienna). 2006 Feb;113(2):231-8. doi: 10.1007/s00702-005-0319-z. Epub 2005 Jun 15.
Neuropeptide Y (NPY) is a neurotransmitter expressed in the central nervous system and involved in learning and memory. The NPY L7P polymorphism has been associated with altered cholesterol levels in obese patients. Since altered cholesterol metabolism is also involved in Alzheimer's disease (AD), the effects of two NPY polymorphisms (L7P and IVS1-100 T/G) on CSF and plasma cholesterol and 24S-hydroxycholesterol were investigated in AD patients and non-demented controls. Furtheremore, the effect of both NPY polymorphisms on the risk of AD was studied. The NPY IVS1-100 T/G polymorphism influenced CSF levels of cholesterol, whereas CSF and plasma levels of 24S-hydroxycholesterol and plasma cholesterol were not altered by genotype. NPY L7P polymorphism did not influence CSF or plasma cholesterol or 24S-hydroxycholesterol. Both NPY polymorphisms did not influence the risk of AD. Our data support the observation, that NPY polymorphisms might influence cholesterol metabolism, but might not act as major risk factor in AD.
神经肽Y（NPY）是一种在中枢神经系统中表达且参与学习和记忆的神经递质。NPY L7P多态性与肥胖患者胆固醇水平改变有关。由于胆固醇代谢改变也与阿尔茨海默病（AD）有关，因此在AD患者和非痴呆对照中研究了两种NPY多态性（L7P和IVS1-100 T/G）对脑脊液和血浆胆固醇以及24S-羟基胆固醇的影响。此外，还研究了两种NPY多态性对AD风险的影响。NPY IVS1-100 T/G多态性影响脑脊液胆固醇水平，而24S-羟基胆固醇的脑脊液和血浆水平以及血浆胆固醇水平不受基因型影响。NPY L7P多态性不影响脑脊液或血浆胆固醇或24S-羟基胆固醇。两种NPY多态性均不影响AD风险。我们的数据支持以下观察结果，即NPY多态性可能影响胆固醇代谢，但可能不是AD的主要危险因素。
